Skip to main content
Back
Watch Compare

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Data quality: 83%
LIXT
Nasdaq Manufacturing Chemicals
$3.05
▲ $0.15 (5.17%)
Mkt Cap: 34.04 M
Price
$2.93
Mkt Cap
34.04 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Negative free cash flow of -3.07 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-218.51%
Below sector avg (-53.53%)
ROIC-145.05%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio10.42
Interest Coverage-557.72

Valuation

PE (TTM)
-5.60
Below sector avg (-1.48)
P/B Ratio6.93
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1366 peers)
Metric Stock Sector Median
P/E -5.6 -1.5
P/B 6.9 1.6
ROE % -218.5 -53.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Analyst Price Target

No analyst coverage available

Earnings Estimates

No forward estimates available

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -6.08 M
ROE -218.51% ROA -183.58%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -3.07 M
ROIC -145.05% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 10.42
Interest Coverage -557.72 Asset Turnover N/A
Working Capital 4.91 M Tangible Book Value 4.91 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -5.60 Forward P/E N/A
P/B Ratio 6.93 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -9.02%
Market Cap 34.04 M Enterprise Value 34.04 M
Per Share
EPS (Diluted TTM) -1.26 Revenue / Share N/A
FCF / Share -0.26 OCF / Share -0.26
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 50.52%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -6.08 M -3.59 M -5.09 M -6.31 M -6.73 M
EPS (Diluted) -1.26 -1.59 -2.66 — —
Gross Profit — — — — —
Operating Income -5.11 M -3.57 M -5.09 M -6.31 M -6.72 M
EBITDA — — — — —
R&D Expenses 254,919.0 726,232.0 898,100.0 1.35 M 1.74 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 9,158.0 16,821.0 16,233.0 8,875.0 7,414.0
Income Tax 1,600.0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 12.73 M 1.15 M 4.31 M 5.56 M 5.09 M
Total Liabilities 1.77 M — — — —
Shareholders' Equity 9.66 M 827,219.0 3.99 M 5.17 M 4.79 M
Total Debt — — — — —
Cash & Equivalents — — 4.20 M 5.35 M 4.82 M
Current Assets 5.18 M — 4.31 M 5.56 M 5.09 M
Current Liabilities 1.33 M 318,284.0 313,858.0 394,786.0 302,926.0